Based on our discussions with physicians, a considerable
number of patients would wait to see PFE's Phase 3 data before deciding which gene
therapy to use. This is because it is not clear if re-treatment is possible, even with a
PFE believes that its hemophilia
A gene therapy may not show the attenuation seen by its competitor. PFE said this is
because of the transient and moderate need for steroids in its patients as well as their
robust durability of factor VIII, substantially above 50% of normal, which is distinct
from competitor studies.